COVID-19 Clinical Trial
Official title:
Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults
The investigators aim to characterise Coronavirus Disease 2019 (COVID-19) in every age group. On the one hand, emphasis is put on the initial presentation, clinical course, outcome and the therapy used. On the other hand further investigations regarding viral and bacterial coinfections, and response of the immune system will be conducted. This study should serve to improve the understanding of COVID-19, to identify risk factors for a severe clinical course and to obtain further insights into pathophysiology of this new infectious disease.
In 2019 the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was identified as the pathogen causing the Coronavirus Disease 2019 (COVID-19) pandemic. Many
retrospective studies have been conducted regarding clinical signs and symptoms and clinical
course of the disease. In most cases the infection causes only light symptoms of the upper
respiratory tract. The infection can also be asymptomatic. However, in some the disease can
cause a severe infection of the lower respiratory tract leading to acute respiratory syndrome
(ARDS) which can be fatal. Especially elderly people suffer from severe disease whereas
children are less compromised.
In this prospective, monocentric study the investigators include patients of all ages with
COVID-19 and also a control group of all ages with respiratory tract infections other than
COVID-19. Initial presentation, clinical course, outcome and the therapy used will be
recorded. Standard diagnostic procedures (vital signs, results of blood samples, blood gas
analysis, x ray, ct scan) will also be recorded. To further characterise the study population
naso- and oropharyngeal swabs will be checked for viral and bacterial coinfections. The
SARS-CoV-2 viral load will be estimated. To characterise the immunological response IgM- and
IgG-antibodies for SARS-CoV-2 will be measured. Moreover lymphocyte typing, cytokine and
chemokine analysis will be conducted. The investigators will also include an analysis of the
proteome in serum and urine. To characterise the virus-host-interaction HLA analysis of the
patients will be conducted. In the case of a medically indicated bronchoscopy bronchoalveolar
lavage will be analysed in regards of viral load, coinfections, lymphocyte typing and
cytokines / chemokines. In case of a medically indicated lung biopsy or in a post mortem lung
biopsy a histological analysis will be made.
In general, samples will be analysed at the initial presentation and after two weeks. Further
analysis will be conducted depending on special events like clinical deterioration. Long-term
follow up will be ensured by telephone visits.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|